Health Information Search Results
Peer Reviewed Scientific Research Reports.
|<< Prev 20 ||Showing 1 to 20 of 25 Matches||Next 20 >>|
1. Twenty-year incidence and patterns of contralateral breast cancer after breast conservation treatment with radiation.
Match Strength: 8.457
PURPOSE: This study was undertaken to determine the incidence of contralateral breast cancer (CLB) after treatment for early-stage breast cancer with breast-conserving treatment (BCT), and to observe patterns of CLB presentation. METHODS: Medical records of 1,801 women treated for unilateral AJCC Stage 0-II breast cancer with BCT between 1977 and 2000 were analyzed as a retrospective cohort. RESULTS: The incidence of any CLB at 20 years was 15.4%. The annual risk of developing any CLB remained constant at approximately 0.75% per year after treatment. The median time to any CLB was 8.2 years ... Read More »
» Published in Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1313-9. Epub 2006 Sep 25.
2. Tumor cell expression of HLA-DM associates with a Th1 profile and predicts improved survival in breast carcinoma patients.
Match Strength: 7.928
Studies aimed at elucidating the immunological and prognostic significance of HLA-DR expression on breast carcinoma cells have yielded contradictory results. To expand on previous studies, we have investigated the associations of tumor cell expression of HLA-DR and its related co-chaperones, invariant chain (Ii) and HLA-DM, with infiltrating inflammatory cells, in situ cytokine mRNA levels and prognosis and outcome in 112 breast carcinoma patients with a median follow-up of 59 months. While the majority of HLA-DR+ tumors co-express Ii, only a minority express HLA-DM. Tumor cell expression of ... Read More »
» Published in Int Immunol. 2006 Nov;18(11):1591-602. Epub 2006 Sep 20.
3. Role of tumor necrosis factor-alpha and its receptors in human benign breast lesions and tumors (in situ and infiltrative).
Match Strength: 7.190
The aim of the present study was to characterize the expression pattern of tumor necrosis factor (TNF)-alpha and its receptors in breast samples (benign diseases, in situ carcinomas and infiltrating carcinomas), and to compare these results with those obtained previously for interleukin-6, p53 and p21 using the same samples in order to elucidate the effects of these cytokines on the proliferation-apoptosis equilibrium. Immunoexpression of TNF-alpha and its receptors (TNFRI and TNFRII) were studied by western blotting and immunohistochemistry. The percentage of samples positive for TNF-alpha ... Read More »
» Published in Cancer Sci. 2006 Oct;97(10):1044-9.
4. In vivo efficacy of STX213, a second-generation steroid sulfatase inhibitor, for hormone-dependent breast cancer therapy.
Match Strength: 6.515
PURPOSE: Steroid sulfatase (STS) inhibitors that can decrease or prevent the biosynthesis of estrogenic steroids via the sulfatase route may play an important role in the treatment of breast cancer. We compare the in vivo efficacy of two potent STS inhibitors, STX64 and STX213, in a xenograft breast cancer model. EXPERIMENTAL DESIGN: MCF-7 cells stably expressing STS cDNA (MCF-7STS) were generated. Ovariectomized MF-1 female nude mice receiving s.c. injections of estradiol sulfate (E2S) and bearing both MCF-7STS and wild-type MCF-7 (MCF-7WT) tumors were orally treated with STX64 and STX213. ... Read More »
» Published in Clin Cancer Res. 2006 Sep 15;12(18):5543-9.
5. A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo.
Match Strength: 6.456
PURPOSE: Integrins are expressed by numerous tumor types including breast cancer, in which they play a crucial role in tumor growth and metastasis. In this study, we evaluated the ability of ATN-161 (Ac-PHSCN-NH2), a 5-mer capped peptide derived from the synergy region of fibronectin that binds to alpha5beta1 and alphavbeta3 in vitro, to block breast cancer growth and metastasis. EXPERIMENTAL DESIGN: MDA-MB-231 human breast cancer cells were inoculated s.c. in the right flank, or cells transfected with green fluorescent protein (MDA-MB-231-GFP) were inoculated into the left ventricle of female ... Read More »
» Published in Mol Cancer Ther. 2006 Sep;5(9):2271-80.
6. Estrogenic regulation of host immunity against an estrogen receptor-negative human breast cancer.
Match Strength: 6.382
PURPOSE: The risk of developing breast cancer is positively correlated with exposure to increased levels of estrogen and/or an increased duration of estrogen exposure. Many different mechanisms have been proposed to explain the association of estrogens with breast cancer risk; however, the well-documented immune modulatory properties of estrogen have received little attention. In part, this is due to a lack of suitable models for studying this relationship. EXPERIMENTAL DESIGN: We have developed an animal model using estrogen receptor (ER)-negative human breast cancer cell line, MDA-MB-468, ... Read More »
» Published in Clin Cancer Res. 2006 Oct 1;12(19):5641-7. Epub 2006 Sep 25.
7. Giant cell tumor of the nasal cavity: case report.
Match Strength: 6.278
Soft tissue giant cell tumor of low malignant potential is a rare tumor located in superficial and deep soft tissue. Tumors with osteoclast-like giant cells have been reported in various sites as breast, salivary glands, lung, kidney and pancreas. These tumors are composed of evenly spaced multinucleated giant cells in a background of mononuclear component composed of round, oval or spindled cells. No atypia or significant mitotic activity is encountered. Immunohistochemical stains for TRAP, smooth muscle actin, desmin and cytokeratins are of great value for diagnosis. Nasal cavity represents ... Read More »
» Published in Eur Arch Otorhinolaryngol. 2007 Feb;264(2):205-8. Epub 2006 Sep 15.
8. Addressing the soy and breast cancer relationship: review, commentary, and workshop proceedings.
Match Strength: 6.132
The impact of soyfood intake on breast cancer risk has been investigated extensively. Much of this focus can be attributed to the soybean being a dietary source that is uniquely rich in isoflavones. The chemical structure of isoflavones is similar to that of estrogen, and isoflavones bind to both estrogen receptors (ER alpha and ER beta) (although they preferentially bind to and activate ER beta) and exert estrogen-like effects under some experimental conditions. Isoflavones also possess nonhormonal properties that are associated with the inhibition of cancer cell growth. Thus, there are ... Read More »
» Published in J Natl Cancer Inst. 2006 Sep 20;98(18):1275-84.
9. Survey on use of postmastectomy radiotherapy for breast cancer in China.
Match Strength: 6.071
Purpose: To comprehensively assess the current use of postmastectomy radiotherapy (PMRT) throughout China. Methods and Materials: A questionnaire on the indications and techniques for PMRT for breast cancer was mailed to all 715 radiotherapy centers in mainland China. Results: Of the 715 questionnaires sent out, 210 were answered (29.4%). The median interval between surgery and PMRT was 6 weeks. "Sandwich" sequencing of chemotherapy and PMRT was the most common combination, performed in 75.7% of the responding clinics. Of the respondents, 11.9% used PMRT for T1-T2N0 breast cancer, 63.8% for T1 ... Read More »
» Published in Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4):1135-42. Epub 2006 Sep 18.
10. Snail and slug play distinct roles during breast carcinoma progression.
Match Strength: 5.978
PURPOSE: Carcinoma progression is linked to a partially dedifferentiated epithelial cell phenotype. As previously suggested, this regulation could involve transcription factors, Snail and Slug, known to promote epithelial-mesenchymal transitions during development. Here, we investigate the role of Snail and Slug in human breast cancer progression. EXPERIMENTAL DESIGN: We analyzed Snail, Slug, and E-cadherin RNA expression levels and protein localization in large numbers of transformed cell lines and breast carcinomas, examined the correlation with tumor histologic features, and described, at ... Read More »
» Published in Clin Cancer Res. 2006 Sep 15;12(18):5395-402.
11. HER-2/neu genotype of breast cancer may change in bone metastasis.
Match Strength: 5.733
The genotype of breast cancer (BRC) is considered to be relatively stable during tumor progression, accordingly, determination of the estrogen receptor and HER-2/neu status is currently based on the primary tumor. However, recent data suggest that the gene expression profile of the metastatic lesion can be different compared to that of the primary BRC. Accordingly, it is possible that the HER-2/neu status is different in the metastatic lesion and the primary BRC. Since the bone is the most frequent metastatic site during the progression of BRC, we have analyzed the HER-2/neu status of 48 bone ... Read More »
» Published in Pathol Oncol Res. 2006;12(3):149-52. Epub 2006 Sep 23.
12. Intravenous delivery of anti-RhoA small interfering RNA loaded in nanoparticles of chitosan in mice: safety and efficacy in xenografted aggressive breast cancer.
Match Strength: 5.429
Overexpression of RhoA in cancer indicates a poor prognosis, because of increased tumor cell proliferation and invasion and tumor angiogenesis. We showed previously that anti-RhoA small interfering RNA (siRNA) inhibited aggressive breast cancer more effectively than conventional blockers of Rho-mediated signaling pathways. This study reports the efficacy and lack of toxicity of intravenously administered encapsulated anti-RhoA siRNA in chitosan-coated polyisohexylcyanoacrylate (PIHCA) nanoparticles in xenografted aggressive breast cancers (MDA-MB-231). The siRNA was administered every 3 days ... Read More »
» Published in Hum Gene Ther. 2006 Oct;17(10):1019-26.
13. The impact of axillary lymph nodes removed in staging of node-positive breast carcinoma.
Match Strength: 5.276
PURPOSE: Number of positive lymph nodes in the axilla and pathologic lymph node status (pN) have a great impact on staging according to the current American Joint Committee on Cancer staging system of breast carcinoma. Our aim was to define whether the total number of removed axillary lymph nodes influences the pN and thus the staging. METHODS AND MATERIALS: The records of 798 consecutive invasive breast cancer patients with T1-3 tumors and positive axillary lymph nodes who underwent modified radical mastectomy between 1999 and 2005 in our hospital were reviewed. The total number of removed ... Read More »
» Published in Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1328-34. Epub 2006 Sep 25.
14. Cost-effectiveness analysis of strategies for HER2 testing of breast cancer patients in France.
Match Strength: 4.884
OBJECTIVES: A cost-effectiveness analysis was conducted comparing diagnostic strategies for determining the HER2 status of invasive breast carcinomas, as an indication for trastuzumab at metastatic relapse. METHODS: A decision tree compared five strategies distinguished by (i) the use of immunohistochemical (IHC) and/or fluorescent in situ hybridization (FISH) techniques, and (ii) the test schedule (at initial diagnosis or metastatic relapse). Most cost and effectiveness data came from a French multicentric study of 2,045 patients from eight hospitals. We were not able to select final criteria ... Read More »
» Published in Int J Technol Assess Health Care. 2006 Summer;22(3):396-401.
15. Moderate coffee and alcohol consumption improves the estrogen metabolite profile in adjuvant treated breast cancer patients: a pilot study comparing pre- and post-operative levels.
Match Strength: 4.876
Most, but not all, studies have found that women with a high urinary 2-hydroxyestrogen (2OHE) to 16alpha-hydroxyestrone (16alphaOHE1) ratio are at reduced risk for breast cancer and have a better prognosis. The aim was to identify factors associated with the pre-operative 2OHE to 16alphaOHE1 ratio and factors that predicted the change in the ratio between the pre-operative visit and first follow-up visit three to six months post-operatively among 59 women with primary ER positive breast cancer tumors. Body measurements, questionnaires and blood samples for measurements of the 2OHE and ... Read More »
» Published in Mol Genet Metab. 2006 Dec;89(4):381-9. Epub 2006 Sep 15.
16. Fluvastatin enhancement of trastuzumab and classical cytotoxic agents in defined breast cancer cell lines in vitro.
Match Strength: 4.703
The combination of anticancer drugs used in the clinic has been based upon empiricism, and the potential permutations of currently available drugs overwhelm the clinical trials system. Recently, investigators have suggested that the combination of a blockade of vital signal transduction pathways in combination with more standard therapy might enhance anticancer effect. Using a panel of breast cancer cell lines and isobologram median effect analysis, a method of determining synergism or antagonism of drugs, we have investigated in vitro potentially clinically useful combinations of agents with ... Read More »
» Published in Breast Cancer Res Treat. 2006 Sep 27;
17. Expression of activated platelet-derived growth factor receptor in stromal cells of human colon carcinomas is associated with metastatic potential.
Match Strength: 4.597
Platelet-derived growth factor receptor (PDGF-R) expression has been reported in a variety of cancers, including colorectal, breast, lung, ovarian and pancreatic cancers, but the role of PDGF-R expression in the development and progression of colon carcinoma has not yet been elucidated. The purpose of this study was to examine the expression of PDGF and PDGF-R in human colon carcinomas. The expression of PDGF, PDGF-R and phosphorylated PDGF-R (p-PDGF-R) was examined by immunofluorescence in 12 surgical specimens of colon carcinoma and in human colon carcinoma cells growing in the subcutis ... Read More »
» Published in Int J Cancer. 2006 Dec 1;119(11):2567-74.
18. A mouse model system to genetically dissect the molecular mechanisms regulating tumorigenesis.
Match Strength: 4.342
The vast majority of human tumors are of epithelial origin and result from the accumulation of mutations that alter the function of pathways that control critical cellular processes, including proliferation, checkpoint regulation, and apoptosis. Authentically replicating these events in animal models is critical to understanding the biology of cancer and for testing the feasibility of novel therapies. We developed a mouse model that recapitulates the steps of epithelial tumor progression of multiple tissue types (kidney, breast, ovarian surface, and prostate epithelia), which takes advantage ... Read More »
» Published in Clin Cancer Res. 2006 Sep 15;12(18):5298-304. Comment in: Clin Cancer Res. 2006 Sep 15;12(18):5274-6.
19. Breast cancer metastasis suppressor 1 functions as a corepressor by enhancing histone deacetylase 1-mediated deacetylation of RelA/p65 and promoting apoptosis.
Match Strength: 4.047
The antiapoptotic transcription factor NF-kappaB is constitutively activated in many cancers and is important for cytokine-mediated progression and metastatic movement of tumors. Breast cancer metastasis suppressor 1 (BRMS1) is a metastasis suppressor gene whose mechanisms of action are poorly understood. In this report, we demonstrate that BRMS1 decreases the transactivation potential of RelA/p65 and ameliorates the expression of NF-kappaB-regulated antiapoptotic gene products. BRMS1 immunoprecipitates with the RelA/p65 subunit of NF-kappaB with protein-protein interactions occurring at the C ... Read More »
» Published in Mol Cell Biol. 2006 Dec;26(23):8683-96. Epub 2006 Sep 25.
20. Intensity modulated radiation therapy: a review of current practice and future directions.
Match Strength: 4.004
The use of intensity modulated radiation therapy (IMRT) has been rapidly growing in the United States. This technology is now being used in a multitude of academic and community centers throughout the country and is being incorporated into the treatment of cancers in almost every anatomical site, most commonly head and neck cancer, central nervous system tumors, and prostate cancer. In addition, current protocols are investigating the use of IMRT for the treatment of breast cancer, lung cancer, abdominal/retroperitoneal malignancies, and gynecological diseases. This article presents a brief ... Read More »
» Published in Technol Cancer Res Treat. 2006 Oct;5(5):447-50.
|<< Prev 20 ||Showing results 1 to 20 of 25||Next 20 >>|
* All information on Level1Diet.com is for educational purposes only. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. Before changing your diet, or adding supplements to your diet, or beginning an exercise program, everyone should consult a qualified and licensed health practitioner; a physician, dietician or similar professional.